Beta Bionics, Inc. (NASDAQ:BBNX) Receives $24.83 Consensus Price Target from Analysts

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $24.83.

BBNX has been the subject of several recent research reports. Bank of America began coverage on Beta Bionics in a research report on Monday, February 24th. They set a “buy” rating for the company. Leerink Partnrs raised shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 24th. Piper Sandler started coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued an “overweight” rating and a $26.00 price objective for the company. Lake Street Capital began coverage on shares of Beta Bionics in a research note on Monday, February 24th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Robert W. Baird started coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target for the company.

Insider Transactions at Beta Bionics

In other news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. The trade was a 34.46 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mike Mensinger purchased 33,350 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the transaction, the insider now directly owns 59,019 shares of the company’s stock, valued at $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Stock Performance

Shares of BBNX opened at $15.10 on Friday. Beta Bionics has a fifty-two week low of $13.64 and a fifty-two week high of $24.50.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.